The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...

Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition ...

Ramucirumab-induced renal dysfunction is rarely reported. The pathology of ramucirumab-associated nephropathy in past reports primarily shows thrombotic microangiopathy (TMA) lesions but podocytopathy ...

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated ...

Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Thymic Carcinoma. According to GlobalData, Phase II drugs for Thymic Carcinoma does not have sufficient ...

This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

CYRAMZA® (ramucirumab, Eli Lilly). Cyramza® was discovered by Eli Lilly and licensed to Innovent for commercialization in Mainland China. Retsevmo® (selpercatinib, Eli Lilly). Retsevmo® was ...

In stage 4, a tumor that began in the liver has spread to either nearby lymph nodes and/or distant lymph nodes and organs.Liver cancer is relatively rare, with under 42,000 cases being diagnosed each ...

Ramucirumab (Cyramza) is used in combination with the targeted drug erlotinib or chemotherapy for management of advanced or metastatic NSCLC. Because of the risks of bleeding, these drugs often aren’t ...